BKA
JUNO

Brick & Kyle Associates’s Juno Therapeutics, Inc. JUNO Stock Holding History

Brick & Kyle Associates’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-200
Closed -$6K – 447
2016
Q3 		$6K Sell
200
-300
-60% -$9.33K ﹤0.01% 378
2016
Q2 		$19K Hold
500
– – 0.02% 279
2016
Q1 		$19K Hold
500
– – 0.02% 266
2015
Q4 		$22K Hold
500
– – 0.02% 240
2015
Q3 		$20K Hold
500
– – 0.02% 259
2015
Q2 		$27K Buy
500
+100
+25% +$5.31K 0.02% 240
2015
Q1 		$24K Buy
400
+200
+100% +$9.71K 0.02% 254
2014
Q4 		$10K Buy
+200
New +$8.95K 0.01% 347

Other funds holding JUNO

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BCM
Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Brick & Kyle Associates's JUNO Position: Q4 2016 in Review

Brick & Kyle Associates sold out of Juno Therapeutics, Inc. (JUNO) in Q4 2016, closing a stake of 200 shares — an estimated $6K sold.

Brick & Kyle Associates first reported a position in JUNO in Q4 2014 and held it in 8 quarters. The position peaked at $27K in Q2 2015. 159 funds tracked by Wall St. Rank hold JUNO as of Q4 2016.

  • Brick & Kyle Associates reported no remaining Juno Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
  • Brick & Kyle Associates sold 200 Juno Therapeutics, Inc. shares in Q4 2016, an estimated $6K.
  • Brick & Kyle Associates first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 8 quarters.
  • Brick & Kyle Associates's Juno Therapeutics, Inc. position peaked at $27K in Q2 2015.
  • 159 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q4 2016.

Based on Brick & Kyle Associates's 13F filing for Q4 2016, filed 5 Jan 2017.